Page 2 - ஒன்றுபட்டது கிஂக்டந் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஒன்றுபட்டது கிஂக்டந். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஒன்றுபட்டது கிஂக்டந் Today - Breaking & Trending Today

Advicenne Receives MHRA Approval to Market Sibnayal (ADV7103) in the UK for the Treatment of dRTA


(1)
Regulatory News:
Advicenne (Euronext: ADVIC), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare renal diseases, is pleased to announce that the Medicines Healthcare products Regulatory Agency (MHRA) has today granted marketing authorisation for Sibnayal (ADV7103) in the UK, for the treatment of distal renal tubular acidosis (dRTA).
With this authorization, and following the recent approval by the European Commission to market Sibnayal for the treatment of dRTA in the European Union, Advicenne is now able to bring to market in the EU and the UK the first and only label-approved drug for the treatment of dRTA in adults, adolescents and children aged one year and older. Advicenne now has the opportunity to make a significant difference to patients suffering from dRTA, classified as an orphan condition in Europe. ....

United Kingdom , United States , France General , Ashley Tapp , Mary Jane Elliott , Davide Salvi , Advicenne Euronext , David Solomon , Didier Laurens , French Financial Markets Authority Autorit , European Union , European Commission , Regulatory Agency , Consilium Strategic Communications , Regulatory News , Medicines Healthcare , Chief Executive Officer , United Kingdon , Euronext Paris , Euronext Brussels , French Financial Markets Authority , General Regulation , Jane Elliott , ஒன்றுபட்டது கிஂக்டம் , ஒன்றுபட்டது மாநிலங்களில் , ஆஷ்லே தட்டவும் ,

Advicenne Receives MHRA Approval to Market Sibnayal™


Advicenne Receives MHRA Approval to Market Sibnayal™ (ADV7103) in the UK for the Treatment of dRTA
July 02, 2021 01:00 ET
| Source:
Advicenne
Advicenne
A
                                                                                                  
Paris, France, 2
nd July 2021 – 7 am CEST – Advicenne (Euronext: ADVIC), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare renal diseases, is pleased to announce that the Medicines & Healthcare products Regulatory Agency (MHRA) has today granted marketing authorisation for Sibnayal™ (ADV7103) in the UK, for the treatment of distal renal tubular acidosis (dRTA).
With this authorization, and following the recent approval by the European Commission to market Sibnayal™ for the treatment ....

United Kingdom , United States , France General , Ashley Tapp , Mary Jane Elliott , Davide Salvi , Advicenne Euronext , David Solomon , Didier Laurens , European Union , European Commission , Regulatory Agency , Consilium Strategic Communications , Advicenne Receives , Market Sibnayal , Chief Executive Officer , United Kingdon , Euronext Paris , Euronext Brussels , Jane Elliott , ஒன்றுபட்டது கிஂக்டம் , ஒன்றுபட்டது மாநிலங்களில் , ஆஷ்லே தட்டவும் , மேரி ஜேன் எலியட் , டேவிட் சால்வி , டேவிட் சாலமன் ,